Severe COVID-19 Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients
Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
Recruiting |
NCT05256511 -
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
|
||
Completed |
NCT04866082 -
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
|
||
Active, not recruiting |
NCT04918901 -
Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
|
||
Recruiting |
NCT05233605 -
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
|
||
Not yet recruiting |
NCT04613986 -
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
|
N/A | |
Recruiting |
NCT05447013 -
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04733833 -
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04712344 -
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
|
Phase 2 | |
Recruiting |
NCT04648410 -
Corticosteroids in Severe COVID-19(ASAP-C Study)
|
||
Enrolling by invitation |
NCT06235866 -
Risk Identification of Long-term Complications
|
||
Recruiting |
NCT05254990 -
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT05596617 -
Safety and Efficacy of Medications COVID-19
|
N/A |